M1FG
NRIX icon

Mach-1 Financial Group’s Nurix Therapeutics NRIX Stock Holding History

Mach-1 Financial Group’s Portfolio NRIX Stock Details NRIX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-32,087
Closed -$365K – 358
2025
Q2 		$365K Buy
+32,087
New +$347K 0.11% 150

Other funds holding NRIX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
CC
Commodore Capital New York $1.73B AUM 298.96% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
VPC
Vestal Point Capital New York $3.58B AUM 189.12% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Mach-1 Financial Group's NRIX Position: Q3 2025 in Review

Mach-1 Financial Group sold out of Nurix Therapeutics (NRIX) in Q3 2025, closing a stake of 32,087 shares — an estimated $365K sold.

Mach-1 Financial Group first reported a position in NRIX in Q2 2025 and held it in 1 quarter. The position peaked at $365K in Q2 2025. 173 funds tracked by Wall St. Rank hold NRIX as of Q3 2025.

  • Mach-1 Financial Group reported no remaining Nurix Therapeutics position as of Q3 2025 after selling out during the quarter.
  • Mach-1 Financial Group sold 32,087 Nurix Therapeutics shares in Q3 2025, an estimated $365K.
  • Mach-1 Financial Group first reported a position in Nurix Therapeutics in Q2 2025 and held it in 1 quarter.
  • Mach-1 Financial Group's Nurix Therapeutics position peaked at $365K in Q2 2025.
  • 173 funds tracked by Wall St. Rank held Nurix Therapeutics as of Q3 2025.

Based on Mach-1 Financial Group's 13F filing for Q3 2025, filed 12 Nov 2025.